Clinical trials: HBOC Syndrome
BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
Neoadjuvant Carboplatin in Triple Negative Breast Cancer
Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15% of all cases diagnosed correspond to the triple negative subtype.
- Trial name
- NCT02978495
- Testing
- Doxorubicin, Carboplatin, Paclitaxel
- Where
- Brazil
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Barretos Cancer Hospital
Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis
Risk-Reducing Surgeries for Hereditary Ovarian Cancer
Based on studies of "Inherited Susceptible Genes Among Epithelial Ovarian Cancer" (NCT03015376, clinicaltrials.gov) and "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer"…
- Conditions
- Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovariectomy, Hysterectomy
- Trial name
- NCT03294343
- Testing
- salpingo-oophorectomy only by laparoscopy, salpingo-oophorectomy with hysterectomy by laparoscopy, Follow-up
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Lei Li
Ovarian Neoplasm Epithelial, Hereditary Breast and Ovarian Cancer Syndrome
Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Purpose: To investigate the prevalence of the germline mutations in the BRCA 1/2 and mismatch repair genes in patients with epithelial ovarian cancer (EOC) and their relatives, and related somatic mutations in tumor tissues in…
- Trial name
- NCT03015376
- Where
- 2 sites in China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer, Ovarian Cancer
Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)
Objectives: To evaluate the attitudes and opinions of women undergoing genetic counseling for hereditary breast and ovarian cancer syndrome, both before and after testing, in regards to pregnancy and fertility Hypothesis…
- Trial name
- NCT00829959
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies.
- Trial name
- NCT02253251
- Testing
- KRAS-variant and microRNA binding site mutation testing
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- MiraKind
BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis.
- Conditions
- BRCA-Mutated Ovarian Carcinoma, BRIP1 Gene Mutation, MSH2 A636P, MLH1 Gene Mutation
- Trial name
- NCT04009148
- Testing
- CASCADE genetic screening
- Where
- United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ
Identifying and Caring for Individuals With Inherited Cancer Syndrome
This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public.
- Conditions
- BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome
- Trial name
- NCT04494945
- Testing
- Biospecimen Collection, Genetic Counseling, Genetic Testing
- Where
- 2 sites in United States
- Volunteers
- 27,500 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute